Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All ivermectin studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19ivm.org COVID-19 treatment researchIvermectinIvermectin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 89% Improvement Relative Risk Ventilation 79% ICU admission 14% Discharge 89% Viral clearance -12% Ivermectin  Ravikirti et al.  EARLY TREATMENT  DB RCT Is early treatment with ivermectin beneficial for COVID-19? Double-blind RCT 112 patients in India (August - October 2020) Lower mortality (p=0.12) and ventilation (p=0.1), not sig. c19ivm.org Ravikirti et al., J. Pharmacy & Pharma.., Jan 2021 Favors ivermectin Favors control

Ivermectin as a potential treatment for mild to moderate COVID-19: A double blind randomized placebo-controlled trial

Ravikirti et al., Journal of Pharmacy & Pharmaceutical Sciences, doi:10.18433/jpps32105
Jan 2021  
  Post
  Facebook
Share
  Source   PDF   All   Meta
Ivermectin for COVID-19
4th treatment shown to reduce risk in August 2020
 
*, now known with p < 0.00000000001 from 103 studies, recognized in 22 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,100+ studies for 60+ treatments. c19ivm.org
RCT with 112 mild and moderate COVID-19 patients in India, showing lower mortality, ventilation, and ICU admission, although not statistically significant due to the small number of events. There was no mortality in the treatment arm (55 patients) versus 7% (4 of 57) in the control arm. The PCR result is subject to confounding by biased loss of followup, with 23 lost in the treatment group and 13 in the control group, and 8 more people in the treatment group discharged before day 6.
Viral load measured by PCR may not accurately reflect infectious virus measured by viral culture. Porter show that viral load early in infection was correlated with infectious virus, but viral load late in infection could be high even with low or undetectable infectious virus. Assessing viral load later in infection may underestimate reductions in infectious virus with treatment.
This is the 11th of 50 COVID-19 RCTs for ivermectin, which collectively show efficacy with p=0.00000014.
This is the 30th of 103 COVID-19 controlled studies for ivermectin, which collectively show efficacy with p<0.0000000001 (1 in 1 sextillion).
risk of death, 88.7% lower, RR 0.11, p = 0.12, treatment 0 of 55 (0.0%), control 4 of 57 (7.0%), NNT 14, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
risk of mechanical ventilation, 79.3% lower, RR 0.21, p = 0.10, treatment 1 of 55 (1.8%), control 5 of 57 (8.8%), NNT 14.
risk of ICU admission, 13.6% lower, RR 0.86, p = 0.80, treatment 5 of 55 (9.1%), control 6 of 57 (10.5%), NNT 70.
risk of no hospital discharge, 88.7% lower, RR 0.11, p = 0.12, treatment 0 of 55 (0.0%), control 4 of 57 (7.0%), NNT 14, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
risk of no viral clearance, 11.6% higher, RR 1.12, p = 0.35, treatment 42 of 55 (76.4%), control 39 of 57 (68.4%).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Ravikirti et al., 9 Jan 2021, Double Blind Randomized Controlled Trial, India, peer-reviewed, 11 authors, study period 1 August, 2020 - 31 October, 2020, average treatment delay 6.1 days, dosage 12mg days 1, 2.
This PaperIvermectinAll
Evaluation of Ivermectin as a Potential Treatment for Mild to Moderate COVID-19: A Double-Blind Randomized Placebo Controlled Trial in Eastern India
Ranjini Roy, Chandrima Pattadar, Rishav Raj, Neeraj Agarwal, Dr Bijit Biswas, Pramod Kumar Manjhi, Deependra Kumar Rai, Anjani Kumar, Asim Sarfaraz, Ranjini Ravikirti, Chandrima Roy, Rishav Pattadar, Bijit Raj, Neeraj Biswas, Pramod Kumar Agarwal, Manjhi, Kumar Deependra, Rai, Anjani Shyama, Asim Kumar, Sarfaraz
There has been a growing interest in ivermectin ever since it was reported to have an in-vitro activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This trial was conducted to test the efficacy of ivermectin in mild and moderate coronavirus disease 19 . Methods: A double blind, parallel, randomised, placebo-controlled trial conducted among adult COVID-19 patients with mild to moderate disease severity on admission in a COVID dedicated tertiary healthcare of eastern India. Enrolment was done between 1 st August and 31 st October 2020. On day 1 and 2 post enrolment, patients in the intervention arm received ivermectin 12 mg while the patients in the non-interventional arm received placebo tablets. Results: About one-fourth (23.6%) of the patients in the intervention arm and onethird (31.6%) in the placebo arm were tested reverse transcriptase polymerase chain reaction (RTPCR) negative for SARS-CoV-2 on 6 th day. Although this difference was found to be statistically insignificant [rate ratio (RR): 0.8; 95% confidence interval (CI): 0.4-1.4; p=0.348]. All patients in the ivermectin group were successfully discharged. In comparison the same for the placebo group was observed to be 93%. This difference was found to be statistically significant (RR: 1.1; 95% CI; 1.0-1.2; p=0.045). Conclusions: Inclusion of ivermectin in treatment regimen of mild to moderate COVID-19 patients could not be said with certainty based on our study results as it had shown only marginal benefit in successful discharge from the hospital with no other observed benefits.
References
Abani, Abbas, Abbas, Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial, Lancet Lond Engl, doi:10.1016/S0140-6736(21)00676-0
Agarwal, Mukherjee, Kumar, Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial), BMJ, doi:10.1136/bmj.m3939
Ahmed, Karim, Ross, A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness, Int J Infect Dis IJID Off Publ Int Soc Infect Dis, doi:10.1016/j.ijid.2020.11.191
Alam, Murshed, Bhiuyan, Saber, Alam et al., Observational Study on Clinical Features, Treatment and Outcome of COVID 19 In A Tertiary Care Centre in India-A Retrospective Case Series, J Bangladesh Coll Physicians Surg, doi:10.3329/jbcps.v38i0.47512
Ashour, Ivermectin: From theory to clinical application, Int J Antimicrob Agents, doi:10.1016/j.ijantimicag.2019.05.003
Babalola, Bode, Ajayi, Ivermectin shows clinical benefits in mild to moderate COVID19: a randomized controlled double-blind, dose-response study in Lagos, QJM Int J Med. Published online, doi:10.1093/qjmed/hcab035
Beigel, Tomashek, Dodd, Remdesivir for the Treatment of Covid-19 -Final Report, N Engl J Med, doi:10.1056/NEJMoa2007764
Caly, Druce, Catton, Jans, Wagstaff, The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antiviral Res, doi:10.1016/j.antiviral.2020.104787
Cao, Wang, Wen, A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19, N Engl J Med, doi:10.1056/NEJMoa2001282
Chaccour, Casellas, Blanco-Di Matteo, The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with nonsevere COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial, EClinicalMedicine, doi:10.1016/j.eclinm.2020.100720
Gonzalez, Gonzalez, Ueno, Ivermectin in Human Medicine, An Overview of the Current Status of Its Clinical Applications, Curr Pharm Biotechnol, doi:10.2174/138920112800399248
Heidary, Gharebaghi, Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen, J Antibiot, doi:10.1038/s41429-020-0336-z
Horby, Lim, Emberson, Dexamethasone in Hospitalized Patients with Covid-19, N Engl J Med, doi:10.1056/NEJMoa2021436
Insiat, Rabby, Current Drugs with Potential for Treatment of COVID-19: A Literature Review, J Pharm Pharm Sci, doi:10.18433/jpps31002
Khan, Khan, Debnath, Ivermectin Treatment May Improve the Prognosis of Patients With COVID-19, Arch Bronconeumol, doi:10.1016/j.arbres.2020.08.007
Kinobe, Owens, A systematic review of experimental evidence for antiviral effects of ivermectin and an in silico analysis of ivermectin's possible mode of action against SARS-CoV-2, Fundam Clin Pharmacol, doi:10.1111/fcp.12644
López-Medina, López, Hurtado, Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19: A Randomized Clinical Trial, JAMA, doi:10.1001/jama.2021.3071
Mahmud, Rahman, Alam, Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial, J Int Med Res, doi:10.1177/03000605211013550
Okumuş, Demirtürk, Çetinkaya, Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients, BMC Infect Dis, doi:10.1186/s12879-021-06104-9
Padhy, Mohanty, Das, Meher, Therapeutic potential of ivermectin as add on treatment in COVID 19: A systematic review and meta-analysis, J Pharm Pharm Sci, doi:10.18433/jpps31457
Rajter, Sherman, Fatteh, Vogel, Sacks et al., Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019: The Ivermectin in COVID Nineteen Study, Chest, doi:10.1016/j.chest.2020.10.009
Shahbaznejad, Davoudi, Eslami, Effect of ivermectin on COVID-19: A multicenter double-blind randomized controlled clinical trial, Clin Ther. Published online, doi:10.1016/j.clinthera.2021.04.007
Sterne, Murthy, Diaz, Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis, JAMA, doi:10.1001/jama.2020.17023
Surkova, Nikolayevskyy, Drobniewski, False-positive COVID-19 results: hidden problems and costs, Lancet Respir Med, doi:10.1016/S2213-2600(20)30453-7
{ 'DOI': '10.18433/jpps32105', 'ISSN': ['1482-1826'], 'URL': 'http://dx.doi.org/10.18433/jpps32105', 'abstract': '<jats:p>Background: There has been a growing interest in ivermectin ever since it was ' 'reported to have an in-vitro activity against severe acute respiratory syndrome coronavirus 2 ' '(SARS-CoV-2). This trial was conducted to test the efficacy of ivermectin in mild and ' 'moderate coronavirus disease 19 (COVID-19). Methods: A double blind, parallel, randomised, ' 'placebo-controlled trial conducted among adult COVID-19 patients with mild to moderate ' 'disease severity on admission in a COVID dedicated tertiary healthcare of eastern India. ' 'Enrolment was done between 1st August and 31st October 2020. \xa0On day 1 and 2 post ' 'enrolment, patients in the intervention arm received ivermectin 12 mg while the patients in ' 'the non-interventional arm received placebo tablets. Results: About one-fourth (23.6%) of the ' 'patients in the intervention arm and one-third (31.6%) in the placebo arm were tested reverse ' 'transcriptase polymerase chain reaction (RTPCR) negative for SARS-CoV-2 on 6th day. Although ' 'this difference was found to be statistically insignificant [rate ratio (RR): 0.8; 95% ' 'confidence interval (CI): 0.4-1.4; p=0.348]. All patients in the ivermectin group were ' 'successfully discharged. In comparison the same for the placebo group was observed to be 93%. ' 'This difference was found to be statistically significant (RR: 1.1; 95% CI; 1.0-1.2; ' 'p=0.045). Conclusions: Inclusion of ivermectin in treatment regimen of mild to moderate ' 'COVID-19 patients could not be said with certainty based on our study results as it had shown ' 'only marginal benefit in successful discharge from the hospital with no other observed ' 'benefits.</jats:p>', 'author': [ {'affiliation': [], 'family': 'Ravikirti', 'sequence': 'first'}, {'affiliation': [], 'family': 'Roy', 'given': 'Ranjini', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Pattadar', 'given': 'Chandrima', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Raj', 'given': 'Rishav', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Agarwal', 'given': 'Neeraj', 'sequence': 'additional'}, { 'ORCID': 'http://orcid.org/0000-0002-7609-6446', 'affiliation': [], 'authenticated-orcid': False, 'family': 'Biswas', 'given': 'Bijit', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Manjhi', 'given': 'Pramod Kumar', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Rai', 'given': 'Deependra Kumar', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Shyama', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Kumar', 'given': 'Anjani', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Sarfaraz', 'given': 'Asim', 'sequence': 'additional'}], 'container-title': 'Journal of Pharmacy &amp; Pharmaceutical Sciences', 'container-title-short': 'J Pharm Pharm Sci', 'content-domain': {'crossmark-restriction': False, 'domain': []}, 'created': {'date-parts': [[2021, 7, 15]], 'date-time': '2021-07-15T22:43:32Z', 'timestamp': 1626389012000}, 'deposited': { 'date-parts': [[2023, 1, 13]], 'date-time': '2023-01-13T13:36:12Z', 'timestamp': 1673616972000}, 'indexed': {'date-parts': [[2024, 4, 8]], 'date-time': '2024-04-08T02:15:56Z', 'timestamp': 1712542556504}, 'is-referenced-by-count': 35, 'issued': {'date-parts': [[2021, 7, 15]]}, 'license': [ { 'URL': 'http://creativecommons.org/licenses/by-sa/4.0', 'content-version': 'unspecified', 'delay-in-days': 0, 'start': { 'date-parts': [[2021, 7, 15]], 'date-time': '2021-07-15T00:00:00Z', 'timestamp': 1626307200000}}], 'link': [ { 'URL': 'https://journals.library.ualberta.ca/jpps/index.php/JPPS/article/download/32105/21639', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://journals.library.ualberta.ca/jpps/index.php/JPPS/article/download/32105/21639', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'member': '1965', 'original-title': [], 'page': '343-350', 'prefix': '10.3389', 'published': {'date-parts': [[2021, 7, 15]]}, 'published-online': {'date-parts': [[2021, 7, 15]]}, 'publisher': 'Frontiers Media SA', 'reference-count': 0, 'references-count': 0, 'relation': {}, 'resource': { 'primary': { 'URL': 'https://journals.library.ualberta.ca/jpps/index.php/JPPS/article/view/32105'}}, 'score': 1, 'short-title': [], 'source': 'Crossref', 'subject': ['Pharmaceutical Science', 'Pharmacology'], 'subtitle': [], 'title': 'Evaluation of Ivermectin as a Potential Treatment for Mild to Moderate COVID-19: A Double-Blind ' 'Randomized Placebo Controlled Trial in Eastern India', 'type': 'journal-article', 'volume': '24'}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit